Fruquintinib Patent Expiration
Fruquintinib is Used for the treatment of metastatic colorectal cancer that is resistant to multiple chemotherapies and targeted therapies. It was first introduced by Takeda Pharmaceuticals Usa Inc
Fruquintinib Patents
Given below is the list of patents protecting Fruquintinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Fruzaqla | US10519142 | Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide | Sep 07, 2035 | Takeda Pharms Usa |
| Fruzaqla | US11046674 | Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide | Sep 07, 2035 | Takeda Pharms Usa |
| Fruzaqla | US7829574 | Substituted quinazoline compounds and their use in treating angiogenesis-related diseases | Mar 23, 2032 | Takeda Pharms Usa |
| Fruzaqla | US8212033 | Use of substituted quinazoline compounds in treating angiogenesis-related diseases | May 09, 2028 | Takeda Pharms Usa |
Fruquintinib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Fruquintinib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
